Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

CMND US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Clearmind Medicine Inc.(CMND US)

$5.97-0.152.52%Ext:$6.06+0.091.55%(Market Closed · 23:51:54 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Clearmind Medicine Inc. — Company Profile

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Adi Zuloff-Shani
Headquarters
Vancouver, Z4, CA
IPO Date
Nov 15, 2022
Employees
4
Website
www.clearmindmedicine.com

Key Metrics

Price
$5.51
Market Cap
$8.19M
Revenue (TTM)
$0.00
Net Income (TTM)
$-2047653.00
EPS (TTM)
-6.78
P/E (TTM)
-1.04
P/B (TTM)
0.71
Dividend Yield
0.00%
ROE (TTM)
-17.82%
ROA (TTM)
-14.10%
Operating Margin
0.00%
Beta
-0.05

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.

Website
www.clearmindmedicine.com
Location
Vancouver, Z4, CA
Phone604 260 1566
Employees4
CEOAdi Zuloff-Shani
Sector
Health Care
Industry
Pharmaceuticals
IPO DateNov 15, 2022

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(352)

Expand
  • SC 13GClearmind Medicine Inc.27 Oct
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER27 Oct
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER16 Oct
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER13 Oct
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER8 Oct
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER7 Oct
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER30 Sep
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER23 Sep
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER17 Sep
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER14 Sep
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER10 Sep
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER8 Sep
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER4 Sep
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER2 Sep
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER1 Sep
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER24 Aug
  • SC 13G/AClearmind Medicine Inc.12 Aug
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER11 Aug
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER6 Aug
  • 6-KREPORT OF FOREIGN PRIVATE ISSUER3 Aug

News

  • Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial27 Oct
  • Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets12 Oct
  • Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder8 Oct
  • Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA7 Oct
  • NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations23 Sep
  • Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations23 Sep
  • Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio17 Sep
  • Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.17 Sep
  • Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial11 Sep
  • Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results8 Sep
  • Clearmind Medicine Stock Slides Friday: What's Happening?4 Sep
  • Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis4 Sep
  • Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled1 Sep
  • Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation24 Aug
  • NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation24 Aug
  • Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial13 Aug
  • Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint13 Aug
  • Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery11 Aug
  • Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study6 Aug
  • Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company3 Aug

Mentions in Filings

  • … ptember 2025, as a director of Fort Technology Inc. (TSXV) since July 2025, as a director of Polyrizon Ltd. (Nasdaq) since May 2024, as a director of Plantify Foods Inc. (TSXV) since August 2023, as a director of <strong>Clearmind Medicine Inc.</strong> (Nasdaq: CMND) since August 2022, as a director of Rani Zim Centers Ltd. (TASE: RANI) since August 2022, and as a director of Gix Internet Ltd. (TASE: GIX) since August 2021. Mr. Itzhaik previously served as a dir …
    Nexentis Technologies Inc.Clearmind Medicine Inc.·PRE 14A - Preliminary proxy statement·Q4 26·20 Oct
  • ***Mr. Oz Adler, CPA***, age 39, has served as Chief Executive Officer of SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company, since January 2022, and as its Chief Financial Officer since April 2018. From September 2017 to March 2018, Mr. Adler served as Vice President of Finance of SciSparc. From December 2020 to April 2021, Mr. Adler served as Chief Financial Officer of Xylo Technologies Ltd. (formerly Medigus Ltd.) (Nasdaq: X …
    Evogene Ltd.Clearmind Medicine Inc.·EX-99.2 - 6-K - EXHIBIT 99.2·Q4 26·6 Oct
  • … ptember 2025, as a director of Fort Technology Inc. (TSXV) since July 2025, as a director of Polyrizon Ltd. (Nasdaq) since May 2024, as a director of Plantify Foods Inc. (TSXV) since August 2023, as a director of <strong>Clearmind Medicine Inc.</strong> (Nasdaq: CMND) since August 2022, as a director of Rani Zim Centers Ltd. (TASE: RANI) since August 2022, and as a director of Gix Internet Ltd. (TASE: GIX) since August 2021. Mr. Itzhaik previously served as a dir …
    Nexentis Technologies Inc.Clearmind Medicine Inc.·PRE 14A - Preliminary proxy statement·Q4 26·5 Oct
  • On November 17, 2022, the Company invested $1,500 in the initial public offering of <strong>Clearmind Medicine Inc.</strong> (“Clearmind”) and received 192 common shares of Clearmind, resulting in the Company holding 9.33% of share capital of Clearmind. As of December 31, 2025, the Company holds 192 common shares of Clearmind, representing a stake of less than 1% of the share capital of Clearmind, at a price of $1.81 per common share. The Company recorded a loss …
    SciSparc Ltd.Clearmind Medicine Inc.·EX-99.1 - 6-K - SCISPARC LTD.'S UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2026·Q2 26·30 Sep
  • We recently entered into a development agreement with <strong>Clearmind Medicine Inc.</strong>, a clinical stage biopharmaceutical company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems. Under this agreement, we will develop a proprietary intranasal formulation of MEAI (5 methoxy 2 aminoindane), Clearmind’s proprietary, next-generation, non-hallucinogenic neuroplastogen drug candi …
    Polyrizon Ltd.Clearmind Medicine Inc.·F-1/A - AMENDMENT NO. 1 TO FORM F-1·Q3 26·28 Sep
  • … age pharmaceutical company focused on developing novel treatments for central nervous system disorders, highlighted the expansion of the U.S. intellectual property portfolio through its ongoing collaboration with <strong>Clearmind Medicine Inc.</strong> (“Clearmind”) (Nasdaq: CMND). As part of the collaboration, three U.S. patent applications have been published covering novel combinations of lysergic acid diethylamide (“LSD”), ketamine and ibogaine with N-acyle …
    SciSparc Ltd.Clearmind Medicine Inc.·EX-99.1 - 6-K - PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA HIGHLIGHTS ENHANCEMENT OF U.S. PATENT PORTFOLIO THROUGH COLLABORATION WITH CLEARMIND COVERING LSD, KETAMINE AND IBOGAINE COMBINATIONS."·Q3 26·24 Sep

Key Stats

Trading

Px/Chg 1D$5.51 / +670.63%
Avg Volume1.46M
Beta-0.05
Mkt Cap8.19M
FD Mkt Cap2.93M

Float

Shrs Out/Float1.49M / 1.10M
Short Float0.27%
Days to Cover1.00
Stock Repurchased$0.00

Current Valuation

EV-3144746.99
EV/EBITDA0.43
EV/Sales0.00
P/B0.71
P/S0.00
FCF Yield-21.90%
ROE-17.82%
ROA-14.10%
Current Ratio4.79

Estimates

P/E-1.04
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMar '23Mar '24Mar '25Mar '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-23.55-43.98-2.22-47.89-19.68-4.00
Price / Sales0.000.000.000.000.000.00
Price / Book Value-34.86-290.8826.7680.988.100.71
Price / Free Cash Flow-30.86-86.25-4.18-51.80-7.51-4.57
ENTERPRISE VALUE METRICS
Enterprise Value161.5436.520.9341.212.1-3.1
Enterprise Value / Sales0.000.000.000.000.000.00
Enterprise Value / EBITDA-22.75-44.80-1.78-51.18-17.992.02
Enterprise Value / EBIT-22.46-44.25-1.77-50.64-17.662.00

Financials

Full Financials
Millions USD5Yr CAGR (%)Oct '21Oct '22Oct '23Oct '24Oct '25
INCOME STATEMENT
Revenue—-----
Gross Income110.2%-0.0-0.1-0.1-0.1-0.0
EBITDA43.4%-3.7-9.7-11.7-6.7-3.7
EBIT74.8%-3.7-9.9-11.8-6.7-3.8
Net Income1.3%-3.7-9.9-11.9-7.3-3.9
EPS (Diluted)-71.7%-473.11-916.44-234.13-9.44-3.03
BALANCE SHEET
Cash & ST Inv10.8%3.70.45.59.65.6
Total Assets9.9%4.21.16.010.16.1
Total Liabilities103%0.32.65.05.84.9
Total Shareholder Equity-25.5%3.9-1.51.04.31.2
CASH FLOW
Net Operating Cash Flow22.9%-2.1-5.1-6.3-6.8-4.7
Cap Ex—-0.2-0.0---
Free Cash Flow20.5%-2.2-5.1-6.3-6.8-4.7

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)5.80
Basic Shares0.19
Market Cap1.1
Diluted Shares0.30
Fully Diluted Shares Outstanding0.30
Fully Diluted Market Cap1.8
+Consolidated Debt0.1
−In-the-Money Convertible Debt—
+Capital Leases0.0
+Operating Leases—
−Cash & Equivalents-11.4
−Short-term Investments-2.2
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value-10.3

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US